Navigation Links
Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
Date:5/17/2011

ATLANTA, May 17, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc. today announced the election Dr. Steven C. Gilman to the Board of Directors of Inhibikase Therapeutics, Inc.

(Logo: http://photos.prnewswire.com/prnh/20110517/CL02791LOGO)

Dr. Steven Gilman joined Cubist Pharmaceuticals in 2008 and currently serves as the Cubist's Executive Vice President, Research & Development and Chief Scientific Officer. Before joining Cubist Pharmaceuticals, Dr. Gilman held several positions with ActivBiotics, Inc., including Chairman of the board of directors and President and CEO. Previously Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager, Inflammation. Additionally, Dr. Gilman served as Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas.

Dr. Gilman currently serves on the Boards of Directors of the Massachusetts Biotechnology Association and the Massachusetts Society for Medical Research. In addition, Dr. Gilman serves on the Science and Regulatory Executive Committee of PhRMA. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.

Dr. Gilman joins Board members Dr. Stephen Fesik, Orrin H. Ingram, II Chair in Cancer Research at Vanderbilt University and former Vice-President for Cancer Research, Abbott Laboratories, Mr. David Gryska, former CFO of Celgene and Ms. Lisa Evren, Vice-President and Treasurer, Talisman-Energy.

"We are fortunate to add Dr. Gilman to the slate of new Board members elected in the last eight months.  Dr. Gilman's breadth of experience in pharmaceutical development and senior leadership will acceler
'/>"/>

SOURCE Inhibikase Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
2. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
3. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
4. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
5. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
6. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
7. Echo Therapeutics Expands Into New Headquarters in Philadelphia
8. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
9. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
10. Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
11. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... 2011 , ReportsnReports adds market ... & Forecasts to 2017 for Greece, Hungary & ... provide value (USD million), volume (units) and average ... within 10 market categories - Cardiac Assist Devices, ...
... Mass., Sept. 20, 2011 Intrinsic Therapeutics, a ... address the spine market,s many unmet needs, today ... and Chief Executive Officer. Mr. Hagan brings over ... field with significant expertise in product development, commercialization ...
Cached Medicine Technology:ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 2ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 3ReportsnReports - Cardiovascular Devices Investment Opportunities, Analysis & 2017 Forecasts: Greece, Hungary, Ireland 4Intrinsic Therapeutics, Inc. Names Cary P. Hagan as President & CEO 2
(Date:7/9/2014)... If you think winning is one of the key ... Winning along with other mental bonuses ranked near the bottom ... one of 11 big fun factors, according to a new ... when it comes to the "fun" factor, very little research ... into this elusive conceptuntil now. , The results of this ...
(Date:7/9/2014)... Medicine at the University of Pennsylvania in collaboration with ... million grant from the National Cancer Institute (NCI) to ... patients with malignant pleural mesothelioma, a rare, aggressive and ... lining of the lungs and is caused almost exclusively ... clinical trial and additional studies looking at the effects ...
(Date:7/9/2014)... stromal support cells and immune cells and the ... the development of diseases could open new therapeutic ... the conclusion of a review article by scientists from ... Nature . , Prof. Peter Carmeliet: "Consider the review ... cancer cells has been examined in minute detail for ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... than watching World Cup highlights, Brian Williams refreshing old ... unfortunate positions on railings. A University of Colorado Cancer ... shows that YouTube also allows researchers, journals, and ... topics of skin cancer and prevention. , "No matter ... of how we communicate around the world," says Chante ...
Breaking Medicine News(10 mins):Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... dressing well given by an emergency doctor. There is no need ... cold. A brisk walk and exposure to sunlight will do you ... you want to avoid the ill-effects of cold weather. Just putting ... the answer. ,Dr Goerge Danke, professor of emergency medicine ...
... According to new study, a protein in the eye has ... researchers say this could lead to promising treatments for other// ... ,Scientists from the Schepens Eye Research Institute in Boston ... a therapeutic drug. The drug can then prevent the onset ...
... that breathing oxygen may cause some harm to cells. The ... people //with severe lung or heart disease.Oxygen supports the organs ... the blood. But oxygen is often given inappropriately. Overall the ... life'. ,A study by researchers at New York Medical ...
... at University of Illinois at Chicago could possibly help ... Dean of the College of Nursing at UIC, //and ... which is using warm booties as a way to ... The idea, says Shaver, is that better sleep occurs ...
... loss followed by weight gain is only a health risk ... are now well established to many. But weight, once lost,// ... that fluctuating weight may, in itself, predispose to heart disease ... a group of 5,428 middle-aged British men during a 12 ...
... observed that yoga therapy can reduce risk factors and improve ... aid improve physical, psychological and spiritual //health - or so ... England, reviewed the best evidence they could find on the ... - out of 11 - trials that were good enough ...
Cached Medicine News:
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Liquichek Urine Chemistry Control is a liquid product ideal for monitoring urine chemistry testing procedures. It provides assayed values for urine tests commonly performed on chemistry analyzers and...
Medicine Products: